Antibody Therapeutics

Technology

Monoclonal antibodies

Monoclonal antibodies are a hugely important human drug class, surpassing $100B in revenue in 2017 and projected to grow at around 12.5% per year into 2023[1]. They are natural molecules that our bodies produce to fight illness, and can be harnessed to treat cancer, inflammation, and a host of other conditions. There is a huge need for these therapies in veterinary medicine, as in the USA alone there are 6M cases of cancer diagnosed each year in dogs, and a similar number in cats[2], and one in four American dogs is diagnosed with some form of arthritis[3].

The first monoclonal antibody for therapeutic use in humans received marketing approval 25 years ago, 80 have since been approved and more than 50 are in late stage clinical development.  In contrast, the use of antibodies in veterinary medicine is in its early stages with just a few antibodies under development.  The limited progress reflects the fact that developing species-specific therapeutic antibodies is technically challenging and only a relatively recent endeavour.  As a result, only one therapeutic antibody has received full marketing approval for dogs and none has been approved so far for cats. 

PetMedix is building platforms that will allow us to harness the huge potential of antibody therapeutics, using the most up to date scientific and technological approaches. We will use our platforms to make high quality, fully species-specific antibodies to a wide range of targets in dogs and cats.

  1. https://globenewswire.com/news-release/2018/04/10/1467446/0/en/Global-Monoclonal-Antibody-Therapeutics-Market-Will-Reach-USD-218-97-Billion-by-2023-Zion-Market-Research.html
  2. Cekanova and Rathore (2014) “Animal models and therapeutic molecular targets of cancer: utility and limitations” Drug design, development and therapy 8:1911-1922
  3. Bland (2015) “Canine osteoarthritis and treatments: a review” Veterinary Science Development 5(2)

The first monoclonal antibody for therapeutic use in humans received marketing approval 25 years ago, 70 have since been approved and more than 50 are in late stage clinical development.  In contrast, the use of antibodies in veterinary medicine is in its early stages with just a few antibodies under development.  The limited progress reflects the fact that developing species-specific therapeutic antibodies is technically challenging and only a relatively recent endeavour.  As a result, only one therapeutic antibody has received full marketing approval for dogs and none has been approved so far for cats.

PetMedix is building a platform that allows us to harness the huge potential of antibody therapeutics, using the latest and best scientific and technological method. We will use our platform to make high quality, fully species-specific antibodies to a wide range of targets in dogs and cats.